






## ORIGINAL ARTICLE

# Characterizing *SOD1* mutations in Spain: The impact of genotype, age and sex in the natural history of the disease

Juan F. Vázquez-Costa<sup>1,2,3</sup>  | Daniel Borrego-Hernández<sup>4</sup> | Carmen Paradas<sup>5,6</sup> |  
 María Teresa Gómez-Caravaca<sup>7</sup> | Ricardo Rojas-García<sup>2,8</sup> | Luis Varona<sup>9</sup> |  
 Mónica Povedano<sup>10</sup> | Tania García-Sobrino<sup>11</sup>  | Ivonne Jericó Pascual<sup>12</sup> |  
 Antonio Gutiérrez<sup>13</sup> | Javier Riancho<sup>14</sup>  | Janina Turon-Sans<sup>8</sup> | Abdelilah Assialioui<sup>10</sup> |  
 Jordi Pérez-Tur<sup>6,15</sup>  | Teresa Sevilla<sup>1,2,3</sup>  | Jesús Esteban Pérez<sup>4</sup> |  
 Alberto García-Redondo<sup>2,4</sup> | on behalf of ALSGESCO

<sup>1</sup>Neuromuscular Unit, Hospital Universitario y Politécnico la Fe, IIS La Fe, Valencia, Spain

<sup>2</sup>Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain

<sup>3</sup>Department of Medicine, Universitat de València, Valencia, Spain

<sup>4</sup>Neurology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain

<sup>5</sup>Hospital Universitario Virgen del Rocío and Instituto Biomedicina de Sevilla, Sevilla, Spain

<sup>6</sup>Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain

<sup>7</sup>Hospital Universitario Reina Sofía, Córdoba, Spain

<sup>8</sup>Motor Neuron Diseases Clinic, Department of Neurology, Biomedical Research Institute Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain

<sup>9</sup>Department of Neurology, Hospital Universitario de Basurto, Bilbao, Spain

<sup>10</sup>Department of Neurology, Hospital de Bellvitge and Idibell, Barcelona, Spain

<sup>11</sup>Department of Neurology, Complejo Hospitalario Universitario de Santiago, Santiago de Compostela (A Coruña), Spain

<sup>12</sup>Hospital Universitario de Navarra (HUN) and IdisNA, Pamplona, Spain

<sup>13</sup>Complejo Hospitalario Universitario Insular-Materno-Infantil de Gran Canaria, Gran Canaria, Spain

<sup>14</sup>Hospital Sierrallana-IDIVAL. Departamento de Medicina y Psiquiatría. Universidad Cantabria, Cantabria, Spain

<sup>15</sup>Unidad Mixta de Neurología y Genética IIS La Fe, Institut de Biomedicina de València-CSIC. CIBERNED, Valencia, Spain

## Correspondence

Juan F. Vázquez Costa, Department of Neurology, Hospital Universitario y Politécnico La Fe, Avenida Fernando Abril Martorell 106, Valencia 46026, Spain.  
 Email: [juan.vazquez@uv.es](mailto:juan.vazquez@uv.es)

## Funding information

Consejería de Educación e Investigación, Grant/Award Number: B2017/BMD-3813; Instituto de Salud Carlos III, Grant/Award Number: 21/00737 PI JFVC, 19/01178 PI TS and PI 19/01543; STOPELA, Grant/Award Number: 2017/0653; European Regional Development Fund

## Abstract

**Background and purpose:** The aim of this study was to describe the frequency and distribution of *SOD1* mutations in Spain, and to explore factors contributing to their phenotype and prognosis.

**Methods:** Seventeen centres shared data on amyotrophic lateral sclerosis (ALS) patients carrying pathogenic or likely pathogenic *SOD1* variants. Multivariable models were used to explore prognostic modifiers.

**Results:** In 144 patients (from 88 families), 29 mutations (26 missense, 2 deletion/insertion and 1 frameshift) were found in all five exons of *SOD1*, including seven novel mutations. A total of 2.6% of ALS patients (including 17.7% familial and 1.3% sporadic) were

See [Appendix 1](#) for all members of ALSGESCO.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](#) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *European Journal of Neurology* published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

estimated to carry *SOD1* mutations. The frequency of this mutation varied considerably among regions, due to founder events. The most frequent mutation was p.Gly38Arg ( $n = 58$ ), followed by p.Glu22Gly ( $n = 11$ ), p.Asn140His ( $n = 10$ ), and the novel p.Leu120Val ( $n = 10$ ). Most mutations were characterized by a protracted course, and some of them by atypical phenotypes. Older age of onset was independently associated with faster disease progression ( $\text{exp}[\text{Estimate}] = 1.03$  [0.01, 0.05],  $p = 0.001$ ) and poorer survival (hazard ratio 1.05 [1.01, 1.08],  $p = 0.007$ ), regardless of the underlying mutation. Female sex was independently associated with faster disease progression ( $\text{exp}[\text{Estimate}] = 2.1$  [1.23, 3.65],  $p = 0.012$ ) in patients carrying the p.Gly38Arg mutation, resulting in shorter survival compared with male carriers (236 vs. 301 months).

**Conclusions:** These data may help to evaluate the efficacy of *SOD1* targeted treatments, and to expand the number of patients that might benefit from these treatments.

#### KEYWORDS

amyotrophic lateral sclerosis, motor neuron disease, mutation, prevalence, prognosis, *SOD1*

## INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that typically affects the upper (UMN) and lower motor neurons (LMN). Approximately 10% of ALS patients report a family history of ALS or frontotemporal dementia (FTD) and are considered to have familial ALS (fALS), while 90% have sporadic ALS (sALS) [1]. Mendelian mutations in more than 20 different genes (<https://alsod.ac.uk/>) have been found to explain approximately 60%–80% of fALS and 10%–20% of sALS [1–3]. The presence of Mendelian mutations in sALS is largely explained by the incomplete penetrance and pleiotropy of many ALS-causing mutations. Moreover, the heritability, at least in some ALS patients, is compatible with an oligogenic origin, where the co-occurrence of two or more mutations is responsible for the emergence and prognosis of the disease [1–4].

An intronic expansion in *C9ORF72* is the most frequent genetic cause of both fALS and sALS in populations of European descent [1], while mutations in *SOD1* are the second cause in those populations and the first cause in non-White patients [5]. More than 200 different mutations, most of them missense and segregating as autosomal dominant mutations, have been described in all five *SOD1* exons in ALS patients (<https://alsod.ac.uk/output/gene.php/SOD1>). Each mutation is associated with different clinical characteristics regarding penetrance, age of onset, progression rate and survival [6, 7]. However, despite some attempts [8, 9], little is known about the effect of other variables such as age and sex on the prognosis of *SOD1* ALS patients.

Interestingly, the type and frequency of each mutation varies considerably among different regions and countries [7]. Up to now, only one small study has reported the prevalence of *SOD1* mutations in a referral centre in Spain, and no prevailing mutation was identified [10]. With the emergence of gene-based therapies [11, 12], it has become a priority to define the natural history of each mutation (or at least the most prevalent ones). The aim of this study, therefore,

was to describe the frequency and distribution of *SOD1* mutations in Spain, and to explore the factors contributing to their phenotype and prognosis.

## MATERIAL AND METHODS


### Study population and data collection

Through the ALS Genetic Spanish Consortium (ALSGESCO), 29 sites treating ALS patients, and performing genetic studies in them, were contacted by the coordinating centres (Hospital la Fe and Hospital 12 Octubre, H12O). Centres were asked to report their local protocols for genetic study (Appendix S1), the total number of ALS patients in their databases, and the number of fALS cases studied for *SOD1*. Sites were also asked to include data on all previously unpublished ALS patients harbouring pathogenic or likely pathogenic variants in *SOD1* according to the American College of Medical Genetics and Genomics (ACMG) guidelines [13]. To that end, a standardized database was sent to sites. Detailed information on the recorded variables can be found in Appendix S1.

Seventeen centres (mostly referral centres), from 14 different regions, sent charts for this study (Figure 1, Appendix S1). All sites except four have their own patient databases, in which they prospectively collect the clinical and genetic data of ALS patients. Thus, although most patients and data were collected prospectively, data on four patients (and some missing data from other patients) were collected retrospectively.

### Data analysis

Demographic, clinical and genetic variables were used to detect duplicates, which were subsequently removed. All variants were



**FIGURE 1** Prevalence of *SOD1* mutations among familial amyotrophic lateral sclerosis (fALS) patients in the different regions of Spain. Warmer colours represent higher percentages. Dark grey represents participating regions without their own databases nor prevalence data, while light grey regions did not participate in this study. The number and most frequent mutations found are displayed for the main participating centres. H12O, Hospital 12 de Octubre; HURS, Hospital Universitario Reina Sofía; HVR, Hospital Virgen del Rocío; HUV, Hospital Universitario Virgen de Valme; CHN, Complejo Hospitalario de Navarra.

designated following the new numbering nomenclature, that is, counting the first (ATG) codon of the sequence NP\_000445. Several databases (Varsome, MiNE, ALSdb and ALSod) and publications [3] were reviewed to confirm the ACMG classification and to exclude benign variants and those of unknown significance. According to their penetrance in both our families and the literature [3], variants were classified as having incomplete penetrance (those found mainly in sALS and/or with several obligate carriers) or high penetrance.

Data are summarized using mean, standard deviation, median, and first and third quartiles for the continuous variables, and relative and absolute frequencies for the categorical variables.

The relationships between demographic (sex), clinical (age of onset, phenotype, and progression rate) and genetic (variant and variant penetrance) variables were explored using density plots, boxplots and bar plots. Subsequently, ordinal, linear or gamma regression mixed models were performed to assess those variables influencing the phenotype, age of onset, and progression rate, respectively, adjusting by the random effect of each mutation. Moreover, these models were repeated only for patients carrying the p.Gly38Arg mutation (the most frequently found in our cohort). Kaplan–Meier curves, log-rank tests, and a Cox regression model, including the genetic variant as a random effect, were used to assess the effect of age and sex on tracheostomy-free survival.

All statistical analyses were performed using R software (version 4.1.1).

## Ethics approval

Participants had consented for the data collection in their respective centres. Information for all patients was de-identified, and data

collection and processing were approved by the Ethics Committee for Biomedical Research of the La Fe Hospital (Valencia) and 12 de Octubre Hospital (Madrid).

## RESULTS

### Study population and clinical characteristics

Thirteen centres had prospectively collected data on 5252 ALS patients (including 656 fALS patients, 12.5%) in their own registries. *SOD1* mutations were found in 116 fALS patients, representing 17.7% of all fALS. However, the frequency varied considerably between regions, with an important cluster in Southern Spain (Figure 1). Moreover, 23 sALS patients harboured a *SOD1* mutation. In H12O, the only centre that systematically studied *SOD1* in sALS, *SOD1* mutations were found in 14 out of 1048 patients (1.3% of sALS). Two population-based studies found that 7.5% of ALS cases in Spain were fALS and 92.5% were sALS [14, 15]. Based on these figures, 2.53% of all ALS patients (1.33% fALS +1.2% sALS) in Spain would carry *SOD1* mutations.

Five additional patients (one with sALS and four with fALS) were sent by the other four centres without prospective registries. Thus, this study includes 144 *SOD1* patients (120 fALS from 64 families and 24 sALS), 51.4% of whom were female. The mean age of motor symptom onset was 43.6 years, usually in the lower limbs (75.6%) and only rarely in the bulbar region (2.3%). Patients usually showed a slow disease progression rate (DPR; median 0.15 points/month), and a long diagnostic delay (median 17.5 months). At diagnosis, 34.7% of patients showed LMN signs only, and only two patients (1.7%) fulfilled the criteria for FTD. At last follow-up, after a median

of 48.7 months, only 30.3% of patients showed bulbar impairment, 44.4% required ventilatory support and 43.2% had died (median survival 226 months). Further details can be found in Appendix S1.

## Genotype–phenotype correlations and geographical distribution

Twenty-nine different pathogenic or likely pathogenic mutations (26 of them missense, 2 deletion/insertion and 1 frameshift) were found in all five exons of *SOD1*, including seven novel mutations in 18 patients of 15 families. Among the novel mutations, two were classified as pathogenic and five as likely pathogenic, according to the ACGM guidelines. The p.Glu41Asp mutation is classified as a variant of unknown significance/likely pathogenic by Varsome and was only found in one sALS patient with LMN-predominant disease and young age of onset. However, this mutation was considered to be likely pathogenic given that: in this patient no other mutations were found after exome sequencing and the *C9ORF72* expansion study; another case with the same mutation (vs. no controls) is reported in the MiNE database; and another missense mutation (p.Glu41Gly) has been reported in the same locus [3]. Altogether, 11 mutations were considered to have high penetrance and 17 incomplete penetrance, based on our own or published data. The main genetic and clinical characteristics of each mutation are summarized in Tables 1 and 2 (full data are provided in Table S1).

The p.Gly38Arg was by far the most frequent mutation in our cohort (40.3%). This mutation was found in 56 patients from 34 kindreds, most of them living in or arising from Southern Spain. p.Gly38Arg caused highly penetrant and early-onset disease (median age 34 years), usually starting in the lower limbs (69%) with a classic ALS (cALS) phenotype (81%) and showing very slow progression and long survival. The second most frequent mutation was p.Glu22Gly (11 patients from six families), mostly found in the Eastern Mediterranean regions of Spain. This variant presents with a similar phenotype to p.Gly38Arg, but with later onset (median age 44 years), strikingly symmetric distance-dependent weakness starting in the lower limbs (100%) and lack of UMN signs (60%). Not surprisingly, before the genetic diagnosis and according to the phenotype and electrophysiological data, some of these patients had been initially diagnosed with distal spinal muscular atrophy (dSMA). The third most frequent variant was p.Asn140His (10 from eight families), also commonly found in the Mediterranean area. This mutation showed a remarkable incomplete penetrance (most cases were sporadic) and phenotype variability, including the site of onset and the prognosis. Specifically, some patients showed a phenotype and family history suggestive of dSMA. Finally, the p.Asp91Ala mutation was found in five patients, in the homozygous state in three of them. Remarkably, one heterozygous patient presented with a Charcot-Marie-Tooth (CMT) phenotype. This patient complained of distal paresthesia, followed by mild weakness in the lower limbs starting at the age of 55 years. The neurological and

neurophysiological examination were compatible with a symmetric sensitive-motor axonal polyneuropathy. However, a gene panel targeting all neuropathy and ALS genes only detected a heterozygous p.Asp91Ala mutation.

Among the novel mutations, the most frequent was the p.Val-120Leu ( $n = 10$ ). This mutation was often found in sALS all over the country with a characteristic phenotype: usually starting quite symmetrical in proximal lower limbs and showing a slow DPR with very rare bulbar involvement. Some of these patients did not show UMN signs and, consequently, had been diagnosed with late-onset proximal SMA (pSMA). Another novel mutation, p.Glu134Ala, was found in three patients of the same family, with a variable phenotype but with surprisingly frequent and early cognitive impairment (one patient had FTD and another had mild cognitive impairment at the time of motor symptom onset). All other mutations affected only a small number of patients and were widely distributed throughout the country.

## Factors influencing the phenotype and prognosis

Table S2 presents the main characteristics of mutations with high versus incomplete penetrance. Most differences found between them might be largely explained by the high-penetrance p.Gly38Arg mutation, which comprised 40% of the total cohort. To avoid this confounding effect, we represented graphically the most relevant variables in each mutation, considering its penetrance. Figure 2 shows that each mutation is characterized by high heterogeneity regarding age of onset (Figure 2a), degree of UMN impairment (Figure 2b), DPR (Figure 2c) and disease duration (Figure 2d). This appears to be independent of their penetrance, except with regard to DPR, where mutations with high penetrance usually showed faster DPR than mutations with incomplete penetrance. However, an effect of the penetrance in the DPR was not statistically confirmed (Estimate = 0.64 [0.22, 1.88],  $p = 0.39$ ).

Multivariable models were also performed to analyse the independent effect of demographic factors (age and sex) on the phenotype and prognosis of patients, adjusting for the random effect of each mutation. The same models were repeated only in patients harbouring the p.Gly38Arg mutation to assess the differential effects of demographic factors according to this specific genotype.

Age of onset was not modified by sex, either in the whole cohort or in p.Gly38Arg patients (Estimate =  $-0.3$  [ $-3.97, 3.42$ ],  $p = 0.87$ ; and Estimate =  $0.89$  [ $-4.26, 6.05$ ],  $p = 0.73$ , respectively). Moreover, the LMN phenotype was also independent of sex and age of onset in both the whole cohort (odds ratio [OR]  $1.36$  [ $0.57, 3.33$ ],  $p = 0.48$ ; and OR  $0.97$  [ $0.93, 1.01$ ],  $p = 0.10$ ) and p.Gly38Arg patients (OR  $1.3$  [ $0.259, 7.29$ ],  $p = 0.75$ ; and OR  $0.98$  [ $0.9, 1.06$ ],  $p = 0.56$ ). Conversely, faster DPR was independently associated with older age of onset ( $\exp[\text{Estimate}] = 1.03$  [ $0.01, 0.05$ ],  $p = 0.001$ ), although not with female sex ( $\exp[\text{Estimate}] = 1.44$  [ $0.97, 2.12$ ],  $p = 0.066$ ) in the whole cohort. Moreover, in patients carrying the p.Gly38Arg mutation,

**TABLE 1** Main genetic characteristics of the SOD1 mutations found in our cohort

Variant	N	Number of families	ACMG classification	ALS type	Inheritance pattern	Penetrance
p.Gly38Arg	58	34 (58.62%)	Pathogenic	fALS	AD	High
p.Glu22Gly	11	6 (54.55%)	Likely pathogenic	fALS	AD	High
p.Asn140His	10	7 (70%)	Likely pathogenic	fALS and sALS	AD	Incomplete
p.Val120Leu <sup>a</sup>	10	10 (100%)	Pathogenic	sALS and fALS	AD	Incomplete
p.Asp91Ala	5	3 (60%)	Pathogenic	fALS and sALS	AD (2) and AR (3)	Incomplete/High
p.Asp77Val	4	3 (75%)	Likely pathogenic	fALS	AD	High
p.Gln23Leu	4	3 (75%)	Likely pathogenic	fALS	AD	High
p.Ile150Thr	4	2 (50%)	Pathogenic	fALS	AD	Incomplete
p.Leu107Val	4	3 (75%)	Likely pathogenic	fALS	AD	High
p.Asn66Ser	3	3 (100%)	Pathogenic	fALS and sALS	AD	Incomplete
p.Glu134Ala <sup>a</sup>	3	1 (33.33%)	Likely pathogenic	fALS	AD	NA
p.Leu85Phe	3	2 (66.67%)	Pathogenic	fALS	AD	High
p.Ser106Leu	3	2 (66.67%)	Likely pathogenic	fALS and sALS	AD	Incomplete
p.Gly94Ser	2	2 (100%)	Pathogenic	fALS	AD	Incomplete
p.Ile113Met	2	1 (50%)	Pathogenic	fALS	AD	High
p.Ile114Thr	2	2 (100%)	Pathogenic	fALS	AD	Incomplete
p.Ile152Thr	2	1 (50%)	Pathogenic	fALS	AD	High
p.Leu118Val	2	1 (50%)	Likely pathogenic	fALS	AD	Incomplete
p.Leu145Phe	2	2 (100%)	Pathogenic	fALS and sALS	AD	Incomplete
p.Arg144Pro <sup>a</sup>	1	1 (100%)	Likely pathogenic	sALS	AD	Incomplete
p.Glu134del	1	1 (100%)	Likely pathogenic	sALS	AD	Incomplete
p.Glu41Asp <sup>a</sup>	1	1 (100%)	Likely pathogenic	sALS	AD	Incomplete
p.His49Arg	1	1 (100%)	Likely pathogenic	sALS	AD	Incomplete
p.Ile113Thr	1	1 (100%)	Pathogenic	fALS	AD	High
p.Leu107_Ser108delinsPro <sup>a</sup>	1	1 (100%)	Likely pathogenic	fALS	AD	High
p.Leu127SerfsTer7 <sup>a</sup>	1	1 (100%)	Pathogenic	fALS	AD	High
p.Lys4Glu	1	1 (100%)	Likely pathogenic	sALS	AD	Incomplete
p.Val15Gly	1	1 (100%)	Likely pathogenic	fALS	AD	Incomplete
p.Val6Met <sup>a</sup>	1	1 (100%)	Likely pathogenic	sALS	AD	Incomplete

Note: The order of the mutations in the table reflects its frequency in our population.

Abbreviations: ACMG, American College of Medical Genetics and Genomics; AD, autosomal dominant; AR, autosomal recessive; fALS, familial amyotrophic lateral sclerosis; sALS, sporadic amyotrophic lateral sclerosis.

<sup>a</sup>Novel mutations.

faster DPR was associated with both older age (exp[Estimate] = 1.08 [1.05, 1.12],  $p < 0.001$ ) and female sex (exp[Estimate] = 2.1 [1.23, 3.65],  $p = 0.012$ ).

Finally, the effects of demographic and genetic variables on survival were assessed. The Kaplan–Meier curves and log-rank tests showed longer median survival in patients with p.Gly38Arg than other mutations (292 vs. 122 months,  $p < 0.0001$ ; Figure 3a), while no statistically significant difference was found in male versus female patients (292 vs. 226 months,  $p = 0.41$ ; Figure 3b). Interestingly, when both variables were considered, sex had a differential effect in patients carrying the p.Gly38Arg mutation and in patients carrying other mutations ( $p < 0.001$ ; Figure 3c). Thus, men carrying the p.Gly38Arg

mutation showed the longest median survival (301 months), followed by women carrying the p.Gly38Arg (236 months) and women carrying other mutations (142 months), while men carrying other mutations showed the shortest survival (120 months). In the Cox regression models, older age was an independent predictor of poor survival in both patients carrying the p.Gly38Arg mutation (hazard ratio [HR] 1.06 [1.01, 1.12],  $p = 0.015$ ) and the whole cohort (HR 1.05 [1.01, 1.08],  $p = 0.007$ ). Moreover, the differential effect of sex according to the underlying mutation was confirmed in the Cox models; after adjusting for age, female sex still showed a strong (although not statistically significant) deleterious effect on survival in the p.Gly38Arg cohort (HR 3 [0.95, 9.50],  $p = 0.062$ ).

TABLE 2 Genotype–phenotype correlation of the SOD1 mutations found in our cohort


Variant	N	AOO Median (1st, 3rd Q)	Female n (%)	Site of onset <sup>a</sup>	Phenotype <sup>a</sup>	DPR Median (1st, 3rd Q)	Bulbar impairment n (%)	Respiratory impairment n (%)	Cognitive impairment (%)
p.Gly38Arg	56	32.4 (25.4, 39.2)	28 (48.28%)	LL, UL, both	cALS, LMN and UMN	0.07 (0.03, 0.15)	13 (31.71%)	12 (28.57%)	MCI (2%)
p.Glu22Gly	11	46 (41.2, 56)	6 (54.55%)	LL	LMN and cALS	0.11 (0.08, 0.13)	2 (20%)	5 (50%)	Alzheimer (11%)
p.Asn140His	10	48.7 (46, 54.3)	5 (50%)	LL, UL and bulbar	LMN and cALS	0.43 (0.27, 0.67)	3 (37.5%)	5 (62.5%)	MCI (20%)
p.Val120Leu <sup>b</sup>	10	61 (52.6, 67.2)	5 (50%)	LL and UL	cALS and LMN	0.11 (0.1, 0.16)	1 (14.29%)	2 (33.33%)	NO
p.Asp91Ala	5	54.54 (50, 57)	3 (60%)	LL	LMN	0.06 (0.06, 0.06)	NO	NO	MCI (25%)
p.Asp77Val	4	62.5 (58, 69.3)	3 (75%)	LL and bulbar	LMN and cALS	1.16 (0.87, 1.44)	1 (50%)	2 (100%)	NO
p.Gln23Leu	4	55.2 (44.5, 65.5)	3 (75%)	LL	cALS and LMN	1.32 (1.03, 1.69)	NA	NA	NO
p.Ile150Thr	4	42 (40, 44)	2 (50%)	LL and UL	cALS	0.48 (0.48, 0.48)	1 (100%)	1 (100%)	NO
p.Leu107Val	4	42.9 (40.9, 45.5)	2 (50%)	LL	LMN	1.04 (1.04, 1.04)	NO	2 (100%)	NO
p.Asn66Ser	3	43.2 (39.7, 57.8)	2 (66.67%)	LL	LMN and cALS	0.07 (0.05, 0.09)	NO	1 (100%)	NO
p.Glu134Ala <sup>b</sup>	3	60 (58.5, 67.5)	3 (100%)	LL and UL	cALS, LMN and UMN	0.56 (0.32, 0.57)	NO	1 (33.33%)	FTD and MCI (66.6%)
p.Leu85Phe	3	35.4 (32.5, 38)	2 (66.67%)	LL	cALS	1.1 (1.01, 1.19)	1 (100%)	1 (100%)	NO
p.Ser106Leu	3	52 (46.5, 54)	1 (33.33%)	UL and LL	cALS and LMN	0.33 (0.31, 0.36)	1 (33.33%)	1 (33.33%)	NO
p.Gly94Ser	2	57.4 (53.6, 61.2)	0 (0%)	LL	LMN	0.56 (0.44, 0.68)	NO	1 (100%)	NO
p.Ile113Met	2	46.5 (44.2, 48.7)	2 (100%)	LL	cALS	0.76 (0.51, 1.01)	1 (50%)	2 (100%)	NO
p.Ile114Thr	2	52 (49, 55)	1 (50%)	LL and UL	cALS and LMN	0.33 (0.21, 0.45)	NO	1 (100%)	NO
p.Ile152Thr	2	29.3 (28.8, 29.8)	1 (50%)	LL	cALS	NA	NA	NA	NO
p.Leu118Val	2	43.85 (38.3, 49.4)	0 (0%)	LL	LMN	0.37 (0.37, 0.37)	1 (100%)	NA	NO
p.Leu145Phe	2	51.6 (46.8, 56.4)	1 (50%)	LL	cALS	0.62 (0.62, 0.62)	1 (100%)	1 (100%)	NO
p.Arg144Pro <sup>b</sup>	1	58.3	1 (100%)	both	NA	1.32 (1.32, 1.32)	NA	NA	NO
p.Glu134del	1	55	1 (100%)	LL	LMN	NA	NA	NA	NA
p.Glu41Asp <sup>b</sup>	1	31.6	1 (100%)	NA	LMN	NA	NA	NA	NO
p.His49Arg	1	61	1 (100%)	LL	NA	NA	NA	NA	NA
p.Ile113Thr	1	NA	0 (0%)	NA	NA	NA	NA	NA	NA
p.Leu107_Ser108delinsPro <sup>b</sup>	1	NA	0 (0%)	NA	NA	NA	NA	NA	NA
p.Leu127SerfsTer7 <sup>b</sup>	1	57.5	0 (0%)	LL	cALS	1.4 (1.4, 1.4)	NA	NA	NO
p.Lys4Glu	1	50	0 (0%)	LL	cALS	NA	NA	NA	FTD
p.Val15Gly	1	30	0 (0%)	LL	LMN	NA	1 (100%)	1 (100%)	NO
p.Val6Met <sup>b</sup>	1	55.5	0 (0%)	LL	LMN	1.44 (1.44, 1.44)	NO	1 (100%)	NO

Note: The order of the mutations in the table reflects its frequency in our population.


Abbreviations: AOO, age of onset; cALS, classic amyotrophic lateral sclerosis; DPR, disease progression rate; FTD, frontotemporal dementia; LL, lower limbs; LMN, lower motor neuron; MCI, mild cognitive impairment; UL, upper limbs; UMN, upper motor neuron.

<sup>a</sup>In these columns the variables are ordered according to its relative frequency in our cohort.

<sup>b</sup>Novel mutations.



**FIGURE 2** Barplots representing the median age of onset (a), proportion of patients with a pure lower motor neuron (LMN) phenotype (b), disease progression rate (c) and disease duration (d), according to the *SOD1* variant. Variants with high penetrance are represented in red and those with incomplete penetrance in blue.



**FIGURE 3** Kaplan-Meier curves representing the survival of *SOD1* amyotrophic lateral sclerosis patients according to genotype (a), sex (b), and both variables (c)

## DISCUSSION

This multicentre study describes the genetic, epidemiological and clinical characteristics of ALS patients harbouring *SOD1* mutations in Spain.

*SOD1* mutations were found in 2.53% of ALS patients in Spain (17.8% of fALS and 1.4% of sALS), representing the second most frequent cause of both fALS and sALS after the *C9ORF72* expansion [16]. These figures are consistent with those found in two small hospital-based studies in Spain [10, 17], in a population-based study in Italy [18] and in a recent meta-analysis in a European population [5]. Considering a population of 47 million in Spain and an estimated prevalence of ALS of 6.89 per 100,000 inhabitants [19], the number of prevalent *SOD1* cases would be 82. Because 63 living patients were identified for this study, we were able to identify 77% of all estimated prevalent *SOD1* patients in Spain [10, 18].

Despite showing a similar prevalence, the *SOD1* mutations found in Spain differed considerably from those found in other European studies. Even among the different regions in Spain there were notable differences due to the existence of several founder effects. Moreover, although *SOD1* patients worldwide share some particularities compared with sALS (earlier age of onset, predominant LMN impairment, rare bulbar onset and rare cognitive impairment), there are also substantial disparities in the phenotype according to the underlying mutation. Thus, the most frequent mutations in Spain have a very slow DPR compared to those found in most countries [6, 8, 20, 21]. The description of the phenotype and natural history of each *SOD1* mutation is key in a context where tofersen (an antisense oligonucleotide) has shown promising results [11, 12] and might be approved. This is, firstly, because the response of each mutation to treatment might be different [12] and it will be important to have historical controls to define its efficacy in clinical practice, and, secondly, because the slow DPR found in many mutations (median DPR  $\leq 0.11$ ) suggests that outcome measures that are more sensitive than the ALSFRS-R or biomarkers will be needed to prove their efficacy. Indeed, in the recent VALOR study, tofersen achieved a relative stabilization of ALSFRS-R in patients carrying more slowly progressing *SOD1* mutations, but failed to show efficacy in this endpoint, given the slow decline of the placebo group [11].

In this study, we report several mutations with a probable founder event in Spain, including seven novel *SOD1* mutations. Briefly, the highly penetrant p.Gly38Arg mutation was found in 40% of our series and was especially frequent in Southern Spain, showing a classic phenotype with a very protracted course. The p.Glu22Gly also shows high penetrance with a characteristic phenotype: symptoms always start in the lower limbs, quite symmetrically, with an LMN-predominant (pseudo-polyneuritic) phenotype, and progress slowly in a distance-dependent manner, mimicking a dSMA. In fact, only 20% of these patients developed bulbar symptoms through the disease course, while some late-onset patients remained with dSMA phenotypes. It is not surprising therefore, that this mutation has been described in dSMA series [22]. Remarkably, in some individuals, the p.Asn140His mutation also showed a phenotype or a family

history suggestive of dSMA, while the p.Asp91Ala mutation was found in heterozygosis in a patient with a CMT phenotype. Finally, the p.Val120Leu, a novel mutation with incomplete penetrance frequently found in our series, usually presented in patients with sALS with proximal weakness in lower limbs followed by proximal upper limbs. The slowly progressive course and the lack of UMN signs in some patients mimicked a pSMA phenotype. In all these cases, other mutations causing those specific phenotypes had been excluded through specific gene panels or clinical exomes. Some studies had reported *SOD1* mutations in patients with atypical phenotypes suggestive of pSMA, dSMA, CMT or spastic paraplegia [20, 23–26], but this study confirms a causal role. Thus, *SOD1* should join the list of genes that can present with a wide spectrum of motor phenotypes (such as *KIF5A*, *CHCHD10*, *VAPB*, *FIG4*) [7, 27, 28], where its analysis should also be considered.

The causes of this pleiotropy are not entirely known. In some genes, a mutational hotspot predisposes to one or another phenotype [27]. In other genes it seems more dependent on other genetic or epigenetic factors because the same mutation can present with different phenotypes in diverse populations [7, 28]. In *SOD1* more than 200 mutations have been described and most of them are associated with a particular phenotype. Our data support previous studies that linked every *SOD1* mutation with a certain phenotype, but the effect of the specific mutations seems to be independent of their exon location or specific penetrance (Table S1, Figure 2). Recent studies suggest that some of this heterogeneity may be explained by the existence of distinct conformations that the *SOD1* protein can adopt to produce the equivalent of prion strains [29].

Even recognizing that the huge heterogeneity of *SOD1* patients can in part be explained by the effect of each mutation, there are still considerable differences among patients harbouring the same mutation. Interestingly, the age of onset and disease progression were found to vary in patients carrying the same *SOD1* mutation but different haplotypes [30], and co-mutations have been described in patients harbouring *SOD1* mutations [31], suggesting that polygenic, epigenetic and environmental factors may also have a role in the disease onset and progression of *SOD1* patients. Previous studies have suggested higher penetrance of *SOD1* mutations in men [6, 9]. However, in our cohort we found no evidence of an effect of sex on penetrance, at least in the most frequent mutations. We did not find an effect of sex on either age of onset or phenotype. Notwithstanding, in patients harbouring the p.Gly38Arg mutation, female sex was independently associated with faster DPR and women showed shorter survival. This effect on DPR and survival was not found when the whole cohort was assessed. Interestingly, another work found worse survival in male *SOD1* patients [9], again suggesting a differential effect of sex on the prognosis according to the underlying mutation. Furthermore, older patients showed faster DPR and shorter survival, independent of the underlying mutation, as has also been found in sALS. Thus, our data suggest that the underlying mutation, age of onset and sex should be considered when assessing the efficacy of *SOD1* targeted treatments.



Our study is one of the largest published series, which expands the previous knowledge on *SOD1* by describing new mutations and phenotypes, and providing a comprehensive overview of their natural history and modifying factors. However, this study also has some limitations. Firstly, it was a multicentre retrospective study and, consequently, there is some risk of bias or missing information, including selection bias. Nevertheless, there was a widespread geographical representation and centres were invited to participate regardless of the presence of *SOD1* patients in their databases. Furthermore, epidemiological data were calculated considering previous population-based studies and all efforts were made to collect all possible data and to standardize these according to current criteria. Secondly, most mutations were found in very few patients and 40% of patients carried the p.Gly38Arg mutation. Thus, the results of the models could be overinfluenced by this mutation. To limit this effect, we used mixed models, adjusting for the random effect of every mutation.

In conclusion, *SOD1* mutations are a frequent genetic cause of sALS and fALS in Spain and are characterized by high geographical and clinical heterogeneity and an overall protracted course. The data presented here may help to evaluate the efficacy of *SOD1* targeted treatments in both clinical trials and clinical practice, and to expand the number of patients that might benefit from these treatments.

#### AUTHOR CONTRIBUTIONS

Juan F. Vázquez-Costa, Alberto García-Redondo and Ricardo Rojas-García are founding members and coordinators of the ALSGESCO, which was supported and funded by CIBERER. Juan F. Vázquez-Costa and Alberto García-Redondo conceived and coordinated the study design, collected the data designed the study, participated in data acquisition and interpretation, and edited the manuscript. Juan F. Vázquez-Costa performed the data analysis and drafted the manuscript. All authors participated in clinical data acquisition, reviewed the paper critically, contributed to scientific and intellectual content and approved the final manuscript. Co-investigators had a minor role in clinical data acquisition.

#### ACKNOWLEDGEMENTS

We would like to thank all the neurologists who helped us with patient recruitment and all patients for their participation in local registries. The samples collection is registered by the National Biobank Register (Instituto de Salud Carlos III, Madrid) coded as C.0004733 and by the Biobank La Fe (PT13/0010/0026).

#### FUNDING INFORMATION

This study has received funding from: Instituto de Salud Carlos III (21/00737 PI J.F.V.C., 19/01178 PI T.S., PI 19/01543 to R.R.), co-funded by European Regional Development Fund ('A way to make Europe'); STOPELA (2017/0653); I+D biomedicina 2017 from Comunidad de Madrid 'ELA-Madrid' (B2017/BMD-3813 to A.G.-R.); *estrategias frente a Enfermedades Neurodegenerativas Ministerio de Sanidad – Comunidad de Madrid B.O.C.M. Num. 142 - Lunes 17 de junio de 2019 - Pág. 10 'Estudio genético de la población con ELA de*

*la Comunidad de Madrid'* to A.G.-R. The Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) are initiatives from the ISCIII. J.F.V.C., T.S., C.P., M.P., R.R.-G., J.T.S. and R.J.M. are members of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD). The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

#### CONFLICT OF INTEREST

Dr Vázquez-Costa is funded by grants from the *Instituto de Salud Carlos III* (JR19/00030, PI Vázquez), has served on advisory boards for Biogen and Hoffmann La-Roche, and has received travel and speaker honoraria from Biogen and Hoffmann La-Roche, outside the submitted work. All other authors have no relevant disclosures to report.

#### DATA AVAILABILITY STATEMENT

Anonymized data not published within this article will be made available by request from any qualified investigator.

#### ORCID

Juan F. Vázquez-Costa  <https://orcid.org/0000-0002-3043-7938>

Tania García-Sobrino  <https://orcid.org/0000-0001-8067-431X>

Javier Riancho  <https://orcid.org/0000-0001-7929-1055>

Jordi Pérez-Tur  <https://orcid.org/0000-0002-9111-1712>

Teresa Sevilla  <https://orcid.org/0000-0003-4716-2667>

#### REFERENCES

- van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. *Lancet*. 2017;390:2084-2098.
- Naruse H, Ishiura H, Mitsui J, et al. Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS. *J Neurol Neurosurg Psychiatry*. 2019;90(5):537-542. doi: 10.1136/jnnp-2018-318568
- McCann EP, Henden L, Fifita JA, et al. Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. *J Med Genet*. 2021;58(2):87-95. <https://jmg.bmj.com/content/58/2/87>
- Morgan S, Shatunov A, Sproviero W, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. *Brain*. 2017;140(6):1611-1618.
- Zou ZY, Zhou ZR, Che CH, Liu CY, He RL, Huang HP. Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry [Internet]*. 2017;88(7):540-549.
- Bali T, Self W, Liu J, et al. Defining *SOD1* ALS natural history to guide therapeutic clinical trial design. *J Neurol Neurosurg Psychiatry*. 2016;88:99-105.
- Yamashita S, Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. *Transl Neurodegener*. 2015;4:13.
- Tang L, Ma Y, Liu XL, Chen L, Fan DS. Better survival in female *SOD1*-mutant patients with ALS: a study of *SOD1*-related natural history. *Transl Neurodegener*. 2019;8(1):2. doi:10.1186/s40035-018-0142-8
- Tang L, Dorst J, Chen L, et al. A natural history comparison of *SOD1*-mutant patients with amyotrophic lateral sclerosis between

- Chinese and German populations. *Transl Neurodegener.* 2021;10:1-3. doi:10.1186/s40035-021-00266-x
10. Gamez J, Corbera-Bellalta M, Nogales G, et al. Mutational analysis of the Cu/Zn superoxide dismutase gene in a Catalan ALS population: should all sporadic ALS cases also be screened for SOD1? *J Neurol Sci.* 2006;247(1):21-28.
  11. Miller TM, Cudkowicz ME, Genge A, et al. Trial of anti-sense oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med.* 2022;383(12):1099-1110.
  12. Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of anti-sense oligonucleotide Tofersen for SOD1 ALS. *N Engl J Med.* 2020;383(2):109-119.
  13. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med.* 2015;17(5):405-424.
  14. Aragonés JM, Altimiras J, Roura-Poch P, et al. Amyotrophic lateral sclerosis: a higher than expected incidence in people over 80 years of age. *Amyotroph Lateral Scler Frontotemporal Degener.* 2016;17(7-8):522-527. doi:10.1080/21678421.2016.1187175
  15. Jericó I, Elizalde-Beiras I, Pagola I, et al. Clinical features and incidence trends of amyotrophic lateral sclerosis in Navarre, Spain, 2007-2018: a population-based study. *Amyotroph Lateral Scler Frontotemporal Degener.* 2021;22(5-6):401-409. doi:10.1080/21678421.2021.1891249
  16. García-Redondo A, Dols-Icardo O, Rojas-García R, et al. Analysis of the C9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. *Hum Mutat.* 2013;34(1):79-82.
  17. García-Redondo A, Bustos F, Juan Y, et al. Molecular analysis of the superoxide dismutase 1 gene in Spanish patients with sporadic or familial amyotrophic lateral sclerosis. *Muscle Nerve.* 2002;26(2):274-278.
  18. Chiò A, Traynor BJ, Lombardo F, et al. Prevalence of SOD1 mutations in the Italian ALS population. *Neurology.* 2008;70(7):533-537. <https://n.neurology.org/content/70/7/533>
  19. Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. *Neuroepidemiology.* 2021;55(5):342-353.
  20. Andersen PM, Nilsson P, Keränen ML, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. *Brain.* 1997;120(10):1723-1737.
  21. Muratet F, Teyssou E, Chiot A, et al. Impact of a frequent nearsplice SOD1 variant in amyotrophic lateral sclerosis: Optimising SOD1 genetic screening for gene therapy opportunities. *J Neurol Neurosurg Psychiatry.* 2021;92(9):942-949. <http://jnnp.bmj.com/>
  22. Frasquet M, Rojas-García R, Argente-Escrig H, et al. Distal hereditary motor neuropathies: mutation spectrum and genotype-phenotype correlation. *Eur J Neurol.* 2021;28(4):1334-1343.
  23. Klein CJ, Wu Y, Duan X, et al. Novel SOD1 mutation discovered in atypical ALS by whole exome sequencing. *J Neurol Neurosurg Psychiatry [Internet].* 2013;84(8):943-944.
  24. Giannini F, Battistini S, Mancuso M, et al. D90A-SOD1 mutation in ALS: the first report of heterozygous Italian patients and unusual findings. *Amyotroph Lateral Scler.* 2010;11(1-2):216-219.
  25. Bernard E, Pegat A, Svahn J, et al. Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study. *Int J Mol Sci.* 2020;21(18):1-11.
  26. Taieb G, Polge A, Juntas-Morales R, et al. Slowly progressive motor neuron disease with multi-system involvement related to p.E121G SOD1 mutation. *Amyotroph Lateral Scler Frontotemporal Degener.* 2017;18(3-4):296-297. doi:10.1080/21678421.2016.1255756
  27. de Boer EMJ, van Rheenen W, Goedee HS, et al. Genotype-phenotype correlations of KIF5A stalk domain variants. *Amyotroph Lateral Scler Frontotemporal Degener.* 2021;22(7-8):561-570. <https://www.tandfonline.com/action/journalInformation?journalCode=iafd20>
  28. Penttilä S, Jokela M, Bouquin H, Saukkonen AM, Toivanen J, Udd B. Late onset spinal motor neuronopathy is caused by mutation in CHCHD10. *Ann Neurol.* 2015;77(1):163-172.
  29. Ayers JI, Borchelt DR. *Phenotypic Diversity in ALS and the Role of Poly-Conformational Protein Misfolding.* Vol 142. Acta Neuropathologica; 2021:41-55.
  30. Henden L, Twine NA, Szul P, et al. Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases. *NPJ Genom Med [Internet].* 2020;5(1):1-8. <https://www.nature.com/articles/s41525-020-00139-8>
  31. McCann EP, Williams KL, Fifita JA, et al. The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia. *Clin Genet [Internet].* 2017;92(3):259-266.

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Vázquez-Costa JF, Borrego-Hernández D, Paradas C, et al. Characterizing SOD1 mutations in Spain: The impact of genotype, age and sex in the natural history of the disease. *Eur J Neurol.* 2023;30:861-871. doi:10.1111/ene.15661

## APPENDIX 1

## Co-investigators from ALSGESCO

Name	Location	Role	Contribution
Alberto Andrés López	Hospital General de Almansa	Head of the Neurology Department	Clinical data acquisition
M. Dolores Calabria	Hospital Universitario de Salamanca	Coordinator of the ALS Unit	Clinical data acquisition
Carmen Díaz-Marín	Hospital General Universitario de Alicante	Head of the Neurology Department	Clinical data acquisition
Eva Fages Caravaca	Complejo Hospitalario de Cartagena	Coordinator of the ALS Unit	Clinical data acquisition
Lucía Galán Dávila	Hospital Clínico Universitario San Carlos	Coordinator ALS Unit	Clinical data acquisition
Alberto García Martínez	Hospital Universitario Central Asturias	Coordinator ALS Unit	Clinical data acquisition
Álvaro Gimenez-Muñoz	Hospital Royo Villanova de Zaragoza	Member of the Neuromuscular Disorders Unit	Clinical data acquisition
Antonio Guerrero Sola	Hospital Clínico Universitario San Carlos	Coordinator ALS Unit	Clinical data acquisition
Javier Mascías Cadavid	Hospital Universitario La Paz – Carlos III	Neurologist ALS Unit	Clinical data acquisition
Jesús S. Mora Pardina	Hospital San Rafael	ALS Unit Coordinator	Clinical data acquisition
José Luis Muñoz Blanco	Hospital Universitario Gregorio Marañón	ALS Unit Coordinator	Clinical data acquisition
Raúl Juntas-Morales	Hospital Vall d'Hebron, Barcelona	Coordinator of the ALS Unit	Clinical data acquisition
Yolanda Morgado	Hospital Universitario de Valme	Coordinator of the Neuromuscular diseases /ALS Unit	Clinical data acquisition
Julio Pardo	Department of Neurology Complejo Hospitalario Universitario de Santiago Santiago de Compostela (A Coruña) Spain	Coordinator of the Neuromuscular diseases /ALS Unit	Clinical data acquisition
Amador Valladares	Hospital Universitario Virgen del Rocío/ Instituto Biomedicina de Sevilla	Member of the Neuromuscular disorders/ALS Unit	Clinical data acquisition
Rosa M. Vilar-Ventura	Hospital General Universitario de Castellón	Coordinator of the ALS Unit	Clinical data acquisition